Aim: The aim of this paper is to summarize the experience and results of deep vein thrombosis prevention after standardized abdominal tumor resection and lymph node dissection, and to investigate standardized treatment methods for postoperative thrombosis prevention. Methods: We performed a retrospective analysis of the clinical data for 548 patients who were given low molecular weight heparin, low molecular weight dextran, or IV salvia to prevent thrombosis development between January 2007 and April 2010 after standardized abdominal tumor resection and lymph node dissection. Patients were divided into the following three groups based on the treatment period and treatment schedule: group 1 included 163 patients who had been treated between January 2007 and March 2008 and received a 7-day course of daily low molecular weight dextran (500 mL) and salvia injection (0.2 g) postoperatively; group 2 included 149 patients who had been treated between April 2008 and March 2009 and received a 7-day course of daily low molecular weight dextran (500 mL), salvia injection (0.2 g), and low molecular weight heparin (40 mg) postoperatively; group 3 included 236 patients who had been treated between April 2009 and April 2010 and postoperatively received a 7-day course of daily low molecular weight dextran (500 mL) and salvia injection (0.2 g), and on postoperative day 3 were started on an additional 7-day course of daily low molecular weight heparin (40 mg). Then, we performed comparative analysis of the treatment efficacy and concomitant symptoms. Results: In group 1, 64 of the 163 cases (39.3%) were positive for D-dimer, and 15 (9.2%) cases were positive for DVT based on Doppler imaging of the lower extremities. In group 2, 38 cases (25.5%) were positive for D-dimer and 3 cases (2.0%) for DVT. In group 3, 62 cases (26.3%) were positive for D-dimer and 6 cases (2.5%) for DVT. In general, the administration of low molecular weight heparin for anticoagulation in groups 2 and 3 led to significant reduction of thromboses when compared to group 1. However, altering the initiation day of low molecular weight heparin administration between groups 2 and 3 did not result in significant differences in the rate of thrombosis formation. Through clinical observation, early administration of low molecular weight heparin may increase adverse effects. Conclusion: We have demonstrated the superior efficacy of postoperative administration of low molecular weight dextran and IV salvia with additional subcutaneous injection of low molecular weight heparin on postoperative day 3 to prevent DVT development after radical resection of abdominal tumors.
Introduction
Deep venous thrombosis (DVT) is a serious complication that occurs after major abdominal surgeries. Complications can vary, and severe cases can be fatal due to thrombotic embolism [1] . Existing data show an incidence rate for DVT of 10% to 63% after orthopedic and general surgery. In addition, postoperative patients with malignant tumors are also at high risk for DVT [2] . Treatment after the formation of thrombosis is often not ideal; therefore, active preventive treatment is critical. In January 2007, the gastrointestinal surgery center at our institution began standardized administration of low molecular weight dextran and IV salvia for patients with standardized resection of stomach, intestine, hepatobiliary, and pancreatic tumors and subsequent lymph node dissection. Starting in April 2008, we have additionally incorporated low molecular weight heparin. By comparing the three clinical stages of our study, we optimized the drug delivery duration and dosage.
Materials and Methods

General Information
Between January 2007 and April 2010, the gastrointestinal surgery center at our institution performed standardized surgical resections of stomach, intestine, hepatobiliary, and pancreatic tumors and lymph node dissection in 548 patients. The study population consisted of 412 males and 136 are females (male to female ratio = 3:1) with an age range from 30 to 92 years (average = 56.0 ± 9.2 years). Radical tumor resections included gastric cancer (243 cases), rectal cancer (140 cases), liver cancer (87 cases), gallbladder cancer (26 cases), pancreatic and ampullary cancer (52 cases). All patients were in good preoperative condition and had no significantly abnormal liver function or blood coagulation and no history of DVT or long-term use of anticoagulation medication. During surgery, complete hemostasis was obtained and no significant perioperative bleeding or errhysis was noted. The study population was divided into three groups by based on timing of three pharmacological adjustments. The sex and age ratios between the three groups were comparable and not significantly different.
Grouping and Drug Regimens
Group 1: Tumor resection surgeries and lymph node dissection procedures were performed between January 2007 and March 2008 in 163 patients. A 7-day course of 500 ml low molecular weight dextran and 0.2 g IV salvia was initiated immediately after surgery. Group 2: Surgeries were performed in 149 patients between April 2008 and March 2009 and a 7-day course of 500 ml low molecular weight dextran, 0.2 g IV salvia, and 40 mg low molecular weight heparin was initiated immediately after surgery. Group 3: Surgery was performed in 236 patients between April 2009 and April 2010 and a 7-day course of 500 ml low molecular weight dextran and 0.2 g IV salvia was administered immediately after the surgery, while a 7-day course of 40 mg low molecular weight heparin was initiated three days after surgery. The medication dosages were adjusted in some patients based on body weight. In cases of concurrent splenectomy, the postoperative platelet count was monitored and, if the value reached more than twice the reference value, a dose of 75 mg clopidogrel was administered orally while the original anticoagulant therapy was terminated. For well-defined thrombosis cases, standardized thrombolytic, anticoagulant, anti-platelet-adhesion therapies were administered. After successful thrombolysis, the patient was started on oral warfarin therapy for 3 to 6 months.
Monitoring Indicators
Patients were examined for calf tenderness and the Homans sign (gastrocnemius pain due to dorsiflexion) after surgery, and any lower extremity edema was noted. Laboratory testing was performed for D-dimer, and a concentration >0.5 mg/L was defined as a positive finding. Lower extremity vascular Doppler ultrasound is the gold standard for the diagnosis of thrombosis [3] .
Statistical Methods
The SPSS13.0 statistical software was used for statistical analysis. Qualitative data are expressed as percentages, rates were compared using the χ 2 test, P < 0.05 was the statistically significant threshold for comparisons between three groups, and P < 0.0125 was the statistically significant threshold for pairwise comparisons. 
Results
Clinical Conditions of Patients in Three Groups after the Surgeries
Incidence of Thrombosis for Three Groups of Patients
Through three adjustments to the clinical therapeutic regimen, the incidence of thrombosis declined to 15 cases (9.2%) in group 1, 3 cases (2.0%) in group 2, and 6 cases (2.5%) in group 3. A statistically significant difference was detected between group 1 (no low molecular weight heparin) and groups 2 and 3 (addition of low molecular weight heparin). However, the difference in incidence between groups 2 and 3, both receiving low molecular weight heparin, was not statistically significant ( Table 1) . During the post-operative follow-up period, the occurrence of thrombosis was 11/125 (8.8%), 2/112 (1.8%), and 3/202 (1.5%) for groups 1, 2, and 3, respectively. The differences between groups 1 and 2 and between groups 1 and 3 were found to be statistically significant, but the difference between groups 2 and 3 was not ( Table 2 ).
Discussion
DTV is caused by abnormal coagulation of blood in the deep veins with perturbations in venous return due to blockage and is a common complication after major general surgery. Beginning at the end of 2006, the gastrointestinal surgery center at our institution performed standardized preventative treatment of deep venous thrombosis for general surgery cases. After three clinical periods, we have identified the optimal duration and dosage for DVT prevention. Our statistical analyses have demonstrated that the thrombosis incidence of groups 2 and 3 is significantly lower than group 1, indicating that the combined administration of three drugs is effective and crucial in the prevention of postoperative thrombosis. During the follow-up period, the thrombosis incidence of groups 2 and 3 remained lower than that of group 1, suggesting that this combination of drugs has long-term efficacy but requires further research.
As a universally-accepted efficacious anticoagulant, low molecular weight heparin does not increase the incidence [4, 5] . In our study, we did not observe abdominal bleeding even in second-surgery cases treated with low molecular weight heparin. Postoperative bleeding is mainly influenced by surgical technique and hemostasis during surgery. However, due to a lack of stable anticoagulant antagonistic drugs, high dosage of low molecular weight heparin is not recommended. Presently, patients that undergo major abdominal surgeries at our hospital are no longer routinely treated with hemostatic drugs if the pre-surgical liver function and coagulation tests are normal and intraoperative hemostasis is complete. For the preventative treatment of thromboses, we implemented the following clinical progression: from January 2007 to March 2008, we only used dextran and IV salvia for thrombosis prevention with the goal to inhibit platelet aggregation and decrease blood viscosity. In April 2008, no more than 40 mg of intradermal low molecular weight heparin was added daily as the standard preventative dose. Theoretically, the preventative efficacy of low molecular weight heparin for thrombosis should improve with early administration. However, our study found that the difference in thrombosis incidence between administration of low molecular weight heparin on the first (group 2) or third postoperative day (group 3) is not statistically significant. In addition, after one year of clinical observations, we found that the administration of low molecular weight heparin on the day of the surgery increases the occurrence of postoperative wound exudate (drainage fluid), peritoneal effusion, and intractable fever (specific cases are described in the supplementary information). Therefore, since April 2009, we have postponed the administration of low molecular weight heparin to postoperative day 3 and, until April of 2010, the clinically observed adverse symptoms have been significantly reduced.
Conclusion
Previous reports in the literature have recommended the administration of low molecular weight heparin for up to 28 days in postoperative abdominal tumor patients [6] . Additional evidence indicates that the standard prophylactic dose of low molecular weight heparin may lead to the decreased endogenous anti-Xa factor level, hence increasing the incidence of DVT [7] . In this retrospective clinical study, we used a triad of drugs for the prevention of thrombosis and clinical groups were divided based on the clinical response. Our understanding of postoperative anticoagulation therapy was gradually improved. During the follow-up period of this study, randomized control trials can lead to results that may be more convincing. We can also expand the sample size, adjust the dosage, and critically analyze the starting point of low molecular weight heparin or the intergroup differences in the duration of drug use. We hope to study the drugs for the prevention of thrombosis in more depth and minimize the adverse effects. In conclusion, we believe the most effective therapy that minimizes side effects for abdominal tumor surgeries postoperatively is a regimen that includes the initiation of a 7-day course of low molecular weight dextran and IV salvia immediately after surgery with the addition of a 7-day course of low molecular weight heparin three days after surgery.
